🎉 M&A multiples are live!
Check it out!

MediWound Valuation Multiples

Discover revenue and EBITDA valuation multiples for MediWound and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

MediWound Overview

About MediWound

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.


Founded

2000

HQ

United States of America
Employees

111

Website

mediwound.com

Financials

LTM Revenue $21.4M

LTM EBITDA -$18.3M

EV

$177M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

MediWound Financials

MediWound has a last 12-month revenue of $21.4M and a last 12-month EBITDA of -$18.3M.

In the most recent fiscal year, MediWound achieved revenue of $20.2M and an EBITDA of -$27.9M.

MediWound expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See MediWound valuation multiples based on analyst estimates

MediWound P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $18.7M $20.2M XXX XXX XXX
Gross Profit $13.2M $3.6M XXX XXX XXX
Gross Margin 70% 18% XXX XXX XXX
EBITDA -$4.8M -$27.9M XXX XXX XXX
EBITDA Margin -26% -138% XXX XXX XXX
Net Profit -$19.6M -$6.7M XXX XXX XXX
Net Margin -105% -33% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

MediWound Stock Performance

As of April 15, 2025, MediWound's stock price is $17.

MediWound has current market cap of $179M, and EV of $177M.

See MediWound trading valuation data

MediWound Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$177M $179M XXX XXX XXX XXX $-2.98

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

MediWound Valuation Multiples

As of April 15, 2025, MediWound has market cap of $179M and EV of $177M.

MediWound's trades at 8.3x LTM EV/Revenue multiple, and -9.6x LTM EBITDA.

Analysts estimate MediWound's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for MediWound and 10K+ public comps

MediWound Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $177M XXX XXX XXX
EV/Revenue 8.7x XXX XXX XXX
EV/EBITDA -6.3x XXX XXX XXX
P/E -5.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -8.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get MediWound Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

MediWound Valuation Multiples

MediWound's NTM/LTM revenue growth is 22%

MediWound's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Over next 12 months, MediWound's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate MediWound's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for MediWound and other 10K+ public comps

MediWound Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 8% XXX XXX XXX XXX
EBITDA Margin -138% XXX XXX XXX XXX
EBITDA Growth 482% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -116% XXX XXX XXX XXX
Revenue per Employee $0.2M XXX XXX XXX XXX
Opex per Employee $0.2M XXX XXX XXX XXX
S&M Expenses to Revenue 16% XXX XXX XXX XXX
G&A Expenses to Revenue 48% XXX XXX XXX XXX
R&D Expenses to Revenue 44% XXX XXX XXX XXX
Opex to Revenue 109% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

MediWound Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

MediWound M&A and Investment Activity

MediWound acquired  XXX companies to date.

Last acquisition by MediWound was  XXXXXXXX, XXXXX XXXXX XXXXXX . MediWound acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by MediWound

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About MediWound

When was MediWound founded? MediWound was founded in 2000.
Where is MediWound headquartered? MediWound is headquartered in United States of America.
How many employees does MediWound have? As of today, MediWound has 111 employees.
Who is the CEO of MediWound? MediWound's CEO is Mr. Ofer Gonen.
Is MediWound publicy listed? Yes, MediWound is a public company listed on NAS.
What is the stock symbol of MediWound? MediWound trades under MDWD ticker.
When did MediWound go public? MediWound went public in 2014.
Who are competitors of MediWound? Similar companies to MediWound include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of MediWound? MediWound's current market cap is $179M
What is the current revenue of MediWound? MediWound's last 12-month revenue is $21.4M.
What is the current EBITDA of MediWound? MediWound's last 12-month EBITDA is -$18.3M.
What is the current EV/Revenue multiple of MediWound? Current revenue multiple of MediWound is 8.3x.
What is the current EV/EBITDA multiple of MediWound? Current EBITDA multiple of MediWound is -9.6x.
What is the current revenue growth of MediWound? MediWound revenue growth between 2023 and 2024 was 8%.
Is MediWound profitable? Yes, MediWound is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.